Latest common stock for AGMB: $300M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
The latest common stock for AGMB is $300M as of June 2026. Investors often review this figure alongside AgomAb Therapeutics N.V. American Depositary Shares's historical trend and sector peers before judging valuation or financial health.
A common stock figure of $300M for AGMB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting AGMB's common stock ($300M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack AgomAb Therapeutics N.V. American Depositary Shares's common stock against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.